Lenacapavir PrEP Marks New Chapter in South African HIV Prevention

João L. Carapinha, Ph.D.

The recent arrival of lenacapavir PrEP in South Africa signals a notable advance in efforts to curb new HIV infections. Officials accepted the first consignment of 37,920 doses around 7 April 2026 through support from the Global Fund. This long-acting injectable requires administration only twice each year and demonstrates impressive efficacy in clinical studies. Decision makers now face the task of integrating the product into existing services while maximising its public health benefit.

South Africa’s Substantial HIV Burden

South Africa faces the largest HIV epidemic globally with approximately 8 million people living with the virus. More than 6 million individuals receive antiretroviral therapy. Although national incidence has declined, certain populations including adolescent girls and young women, sex workers and men who have sex with men still experience high rates of new infections. Oral pre-exposure prophylaxis programmes have recorded over 1.3 million initiations yet adherence frequently limits real-world effectiveness.

Strong Clinical Results from Key Trials

Clinical trials provide robust evidence for lenacapavir PrEP. Researchers conducting the PURPOSE 1 trial among adolescent girls and young women in South Africa and Uganda reported zero HIV infections in participants who received the injectable. This result compares favourably with a background incidence rate of 2.41 per 100 person-years. The study also found the medicine statistically superior to daily oral Truvada. In the PURPOSE 2 trial, which enrolled diverse populations across several countries including South Africa, investigators documented a 96 percent reduction in HIV incidence compared with background rates. These findings indicate that lenacapavir PrEP could substantially improve prevention outcomes for groups that struggle with daily tablet regimens.

Market Access Through International Collaboration

A grant of 29 million US dollars from the Global Fund made the initial delivery possible. Gilead Sciences coordinated with the South African Department of Health and SAHPRA, the national regulatory authority. SAHPRA granted approval on 27 October 2025 thereby positioning South Africa as the first African country to authorise this medicine for PrEP use. This process highlights effective cooperation between governments, multilateral organisations and pharmaceutical manufacturers.

Health Economics and Long-term Sustainability

Health economists will scrutinise the introduction of lenacapavir PrEP carefully. Lifetime costs associated with HIV treatment and care place considerable pressure on public finances. Models suggest the injectable may deliver strong value if it achieves high adherence rates and prevents infections among high-risk individuals. Local production under voluntary licences could reduce costs significantly in subsequent years. The government issued a call for expressions of interest from domestic manufacturers in March 2026. Such measures support South Africa’s strategy to develop its pharmaceutical sector and improve medicine affordability across the continent.

System Dynamics and Implementation Requirements

Several practical considerations will shape the programme’s success. Healthcare workers need appropriate training on administration and patient education. Counsellors must inform users about the gradual decline in drug levels after each injection to ensure they adopt alternative protection if the next dose is delayed. Supply chain managers face the challenge of accurate forecasting for a medicine with six-month dosing intervals. The Department of Health plans to begin with high-incidence districts and expand gradually as capacity allows. This measured approach permits collection of local data on uptake, safety and service delivery models.

Recommendations for Decision Makers

  • Establish comprehensive monitoring systems from the outset to generate real-world evidence on effectiveness and safety.
  • Pursue pricing agreements that reflect both the clinical benefits and South Africa’s economic context.
  • Design service delivery models that incorporate community venues and reduce barriers to access.
  • Engage communities early to build understanding and trust in the new option.
  • Accelerate technology transfer to enable local generic manufacturing within the next two years.

The arrival of this consignment therefore creates a foundation for meaningful progress. With careful planning and sustained collaboration South Africa can translate clinical promise into reduced incidence rates. The experience will also offer valuable lessons for other countries seeking to introduce long-acting prevention technologies in similar settings. Ongoing analysis of implementation data remains essential to refine strategies and inform future policy decisions.